

FOR IMMEDIATE RELEASE

IntegraGen Reports 17% Revenue Growth During First Half of 2018

- Revenues of €3.6 million, up 17% compared to the first half of 2017
- + 20% growth in genomics activities, primarily due to the increase in services provided to customers in the research segment
- Partnership agreements in the fields of clinical diagnostics and interpretative software

Evry, France (July 9, 2018) - IntegraGen (FR0010908723: ALINT - PEA-SME Eligible), a company specializing in the transformation of data from biological samples into genomic information and diagnostic tools for oncology, today announces its sales revenue for the first half of 2018.

Genomics activities posted growth of +20%, primarily as a result of growth in services provided to customers in the research segment

IntegraGen's 2018 revenue was €3.6 million as June 30, 2018, an increase of 17% compared to the first half of 2017. Genomics business for the "clinical research" segment associated with the company's site in Villejuif on Gustave Cancer Roussy's Campus and microbiology-related business at the Pasteur Institute remained at a high level of €0.9 million, even if slightly lower than the first-half of 2017. Genomic services activity for client-based "research" amounted to € 2.7 million, an increase of 42% over the same period during 2017.

The return to significant growth during the first half of 2018 follows a strong increase in orders received in the second half of 2017 which were realized in Q1 2018, improved competitiveness of the company's offerings as a result of new sequencing protocols developed in partnership with Twist Bioscience, and positive general market dynamics.

In early 2018 the company announced the launch of two separate Big Data SaaS solutions, SIRIUS™ and MERCURY™, both of which enable the high-performance exploration of large scale genomic data to assist diagnosis and care of patients. Nearly 2,000 samples were analyzed using these solutions during the first half of 2018.

Partnership agreements in the fields of clinical diagnostics and interpretative software

In the first half of 2018 IntegraGen announced two separate partnership agreements with Twist Bioscience. The first agreement focuses on IntegraGen's use of Twist's exome capture kits and enable a significant competitive advantage for IntegraGen in the field of genomic sequencing. The second agreement enables Twist Bioscience's salesforce to distribute the company's SIRIUS™ and MERCURY™ genomic interpretation software tools on a worldwide basis. In parallel, IntegraGen also announced the signing of a North American licensing agreement with GoPath Laboratories (Chicago, Illinois) for the company's theranostics miR-31-3p test. GoPath launched the test during the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in June 2018 in Chicago.

On the occasion of the announcement of the company's sales revenue, Bernard Courtieu, Chairman and CEO of the company said: "IntegraGen returned to double-digit growth in the first half of 2018.

This performance is the result of efforts to improve competitiveness and development efforts by IntegraGen's technical, bioinformatics and commercial teams."

IntegraGen will publish its half-year results on September 28, 2018.

ABOUT INTEGRAGEN

IntegraGen is a company specializing in deciphering the human genome and producing relevant and easily interpretable data for academic and private laboratories. IntegraGen's oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients. As of December 31, 2017, IntegraGen had 40 employees and had generated revenue of €6.1 million in 2017. Based in Evry Genopole, IntegraGen also has an U.S. office in Cambridge, Massachusetts. IntegraGen is listed on Euronext Growth (ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).

For more information, visit www.integragen.com



INTEGRAGEN CONTACTS

IntegraGen

Bernard COURTIEU
President and CEO

Laurence RIOT LAMOTTE
Chief Financial Officer
contact@integragen.com
Tel.: +33 (0)1 60 91 09 00

NewCap

Investor and Media Relations
Louis-Victor DELOUVRIER
integragen@newcap.eu
Tel.: +33 (0)1 44 71 98 53